Vyome Holdings presents Phase 2 study results on VT-1953

Vyome Holdings (HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds, MFW, at the 2026 American Association for Cancer Research, AACR, Annual Meeting in San Diego, on April 21, 2026. Key highlights: VT-1953 topical gel significantly reduced MFW-associated severe malodor over a 14 Day period as scored by investigators. VT-1953 efficacy was significantly superior to the vehicle control; 70% of patients treated with VT-1953 vs 0% of patients treated with vehicle reported an improvement in patient-reported outcome measure of impact of malodor on life by Day 14; Patients treated with VT-1953 reported a clinically significant 2 point improvement in lesion pain by Day 14 as scored using a 10-point VAS scale. No change seen in vehicle-treated arm.